Cargando…
Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees
Dengue virus (DENV) infects an estimated 390 million people each year worldwide. As tetravalent DENV vaccines have variable efficacy against DENV serotype 2 (DENV2), we evaluated the role of genetic diversity within the pre-membrane (prM) and envelope (E) proteins of DENV2 on vaccine performance. We...
Autores principales: | Martinez, David R., Yount, Boyd, Nivarthi, Usha, Munt, Jennifer E., Delacruz, Matthew J., Whitehead, Stephen S., Durbin, Anna P., de Silva, Aravinda M., Baric, Ralph S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583086/ https://www.ncbi.nlm.nih.gov/pubmed/33027653 http://dx.doi.org/10.1016/j.celrep.2020.108226 |
Ejemplares similares
-
Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization
por: Gallichotte, Emily N., et al.
Publicado: (2018) -
Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines
por: Swanstrom, Jesica A, et al.
Publicado: (2019) -
Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes
por: Gallichotte, Emily N., et al.
Publicado: (2018) -
Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4
por: Widman, Douglas G., et al.
Publicado: (2017) -
A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
por: Nivarthi, Usha K., et al.
Publicado: (2021)